Lonza Group AG stock (CH0013841017): 2025 revenue up 9% to CHF 8.7 billion

Lonza Group AG, a leading contract development and manufacturing organization (CDMO), released its full-year 2025 results on February 27, 2026, posting revenue of CHF 8.7 billion, a 9% increase at constant exchange rates from the prior year. The growth was fueled by strong performance in biologics and cell & gene therapies, key segments supporting global biopharma innovation, according to Lonza IR as of 02/27/2026.

The results highlight Lonza's pivotal role in providing manufacturing services to US biotech firms amid rising demand for advanced therapies. Shares of Lonza Group AG (SWX: LONN) traded at CHF around 400 levels post-results, reflecting market confidence in its CDMO leadership, per exchange data.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Lonza Group AG: core business model

Lonza Group AG operates as a global CDMO, specializing in the development and manufacturing of biologics, small molecules, and advanced therapies including cell and gene treatments. The company supports biotech and pharmaceutical firms from early-stage development through commercial-scale production, with a focus on high-value modalities.

Headquartered in Basel, Switzerland, Lonza maintains extensive manufacturing capacity across North America, Europe, and Asia, enabling it to serve major US clients like Moderna and other biotech innovators. This global footprint positions it as a key partner in the biopharma supply chain relevant to US investors tracking contract manufacturing trends.

Main revenue and product drivers for Lonza Group AG

Biologics contract manufacturing represented a primary revenue driver in 2025, contributing significantly to the 9% growth reported on February 27, 2026, according to Lonza IR as of 02/27/2026. Cell & gene therapy services also advanced, capitalizing on surging demand for personalized medicines.

The company's diversified portfolio includes microbial and mammalian manufacturing, alongside analytical services, which bolster resilience against sector volatility. US market exposure remains strong, with facilities in Houston and Portsmouth supporting domestic biotech growth.

Industry trends and competitive position

The CDMO sector benefits from biopharma outsourcing trends, with US firms increasingly relying on specialists like Lonza for complex manufacturing. Lonza's investments in modular facilities and biosafety enhancements strengthen its edge over peers in scaling advanced therapies.

Competitors include Thermo Fisher and Catalent, but Lonza's focus on biologics and next-gen modalities aligns with US innovation hubs like Boston and San Francisco, per industry reports.

Why Lonza Group AG matters for US investors

Lonza's partnerships with US biotechs provide indirect exposure to American drug pipelines, including mRNA and gene therapies critical to the US healthcare economy. Its Swiss listing offers US investors a way to access global CDMO growth without direct biotech volatility.

Conclusion

Lonza Group AG's 2025 results affirm its leadership in the CDMO space, with revenue growth underscoring demand for biologics and advanced therapies. The company's US-centric operations and global scale continue to drive value amid biopharma expansion. Investors monitor upcoming quarterly updates for sustained momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.